The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Merck KGaA

Monday Biotech Deal Review: July 19, 2010

Lots of deals this week. Some good news, some bad news. On the good news front, a steady volume of securities and M&A activity is continuing through the summer; and one Canadian firm benefits from the U.S. Defense Departments exploration of RNAi products as anti-virals. On the other hand front, though, a licensing option expired, a liquidation proceeded and marketing rights were voluntarily surrendered. See who’s who after the jump…

Monday Deal Review: March 30, 2009

Canadian deal and company info from this week after the jump…

New Merck Serono Biotechnology Ventures Fund

Merck KGaA, the Darmstadt-based company (not part of Merck & Co. Inc. of the U.S.),  is starting a biotechnology venture capital fund that will invest €40 million ($55 million) in emerging biotech companies during the next five years, with a focus on the core therapeutic areas of Neurodegenerative Diseases, Oncology, Autoimmune & Inflammatory Diseases, Endocrinology and Fertility, as well as enabling tool and discovery technologies.  Companies wishing to submit proposals or receive additional information can contact Merck Serono Ventures via their website.

Bookmark and Share


Get every new post delivered to your Inbox.

Join 128 other followers